2,749 reports of this reaction
2.1% of all CYCLOBENZAPRINE reports
#6 most reported adverse reaction
CHRONIC KIDNEY DISEASE is the #6 most commonly reported adverse reaction for CYCLOBENZAPRINE, manufactured by Cipla USA Inc.. There are 2,749 FDA adverse event reports linking CYCLOBENZAPRINE to CHRONIC KIDNEY DISEASE. This represents approximately 2.1% of all 129,800 adverse event reports for this drug.
Patients taking CYCLOBENZAPRINE who experience chronic kidney disease should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CHRONIC KIDNEY DISEASE is a less commonly reported adverse event for CYCLOBENZAPRINE, but still significant enough to appear in the safety profile.
In addition to chronic kidney disease, the following adverse reactions have been reported for CYCLOBENZAPRINE:
The following drugs have also been linked to chronic kidney disease in FDA adverse event reports:
CHRONIC KIDNEY DISEASE has been reported as an adverse event in 2,749 FDA reports for CYCLOBENZAPRINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
CHRONIC KIDNEY DISEASE accounts for approximately 2.1% of all adverse event reports for CYCLOBENZAPRINE, making it a notable side effect.
If you experience chronic kidney disease while taking CYCLOBENZAPRINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.